1 Min Read
FRANKFURT, June 3 (Reuters) - Bayer AG : * Says Bayer to evaluate riociguat in new indication * Says phase iib study to investigate riociguat in pulmonary hypertension
associated with idiopathic interstitial pneumonia
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.